Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 29 of 29 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/07/21
End: 05/30/22
Due: 05/30/23
Phase: N/A
Priority: Normal
Start: 12/31/19
End: 12/31/25
Due: 12/31/26
Phase: N/A
Priority: Normal
Start: 03/12/25
End: 12/30/28
Due: 12/30/29
Phase: N/A
Priority: Normal
Start: 01/15/25
End: 12/30/27
Due: 12/30/28
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma | NCT04601610 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | user2@example.com | None | 2021-06-07 | 2022-05-30 | 2023-05-30 | - | - | 2025-07-14 |
| Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer | NCT04165993 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | user2@example.com | None | 2019-12-31 | 2025-12-31 | 2026-12-31 | - | - | 2025-07-14 |
| Evaluation of JSKN016 Combination Therapy in Subjects with NSCLC | NCT06868732 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | user2@example.com | None | 2025-03-12 | 2028-12-30 | 2029-12-30 | - | - | 2025-07-14 |
| JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer | NCT06751485 | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | user2@example.com | None | 2025-01-15 | 2027-12-30 | 2028-12-30 | - | - | 2025-07-14 |